The New York Entrepreneur

Ozempic maker Novo Nordisk misses profit estimates as it builds out capacity

Read Time:11 Second

Novo Nordisk, Europe’s largest company by market cap thanks to its wildly popular weight-loss drugs, managed just a small increase in second-quarter profits as it builds out the capacity to make the products.

About Post Author

Happy
Happy
0 %
Sad
Sad
0 %
Excited
Excited
0 %
Sleepy
Sleepy
0 %
Angry
Angry
0 %
Surprise
Surprise
0 %
Previous post Wegovy maker Novo Nordisk posts earnings miss, cuts operating profit outlook
Next post Puma shares slump after sportswear group trims profit forecasts